Glenmark Pharmaceuticals ltd — Capital/Financing Update 2021

Feb 11, 2021

==> picture [16 x 10] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 42] intentionally omitted <==

February 11, 2021

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001.

To, The Manager – Listing, The National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%

With reference to the subject mentioned above, kindly find attached media release which is self‐explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK VINAYAK KUBER Date: 2021.02.11 KUBER 10:09:22 +05'30' Harish Kuber Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [565 x 76] intentionally omitted <==

Press Release For Immediate Release

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%

Mumbai, India; February 11, 2021: – Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Gel USP, 1%, the generic version of Cleocin T®[1] Gel, 1%, of Pharmacia & Upjohn.

According to IQVIA[TM] sales data for the 12 month period ending December 2020, the Cleocin T® Gel, 1% market[2] achieved annual sales of approximately $73.8 million*.

Glenmark’s current portfolio consists of 169 products authorized for distribution in the U.S. marketplace and 42 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index.

For more information, visit www.glenmarkpharma.com

==> picture [562 x 27] intentionally omitted <==

==> picture [565 x 76] intentionally omitted <==

For more information:

Glenmark Media Contacts

Udaykumar Murthy Senior Manager, Corporate Communications +91 9960377617 corpcomm@glenmarkpharma.com

1All brand names and trademarks are the property of their respective owners.

2Market includes brand and all available therapeutic equivalents

*IQVIA[TM] National Sales Perspectives: Retail & Non-Retail, December 2020

==> picture [562 x 27] intentionally omitted <==